CSPC PHARMACEUTICAL (CVG BE) stock market data APIs
€0.8456
0(0%)
as of December 18, 2025
Try our APIs with
free plan!
CSPC PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for CVG.BE.
Prev. Close
0.8456
Open
0.8456
High
0.8456
Low
0.8456
52 wk Range
0.5016-1.2081
Market Cap
11 678 M
Dividends (Yield)
0.0963
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSPC PHARMACEUTICAL data using free add-ons & libraries
Get CSPC PHARMACEUTICAL Fundamental Data
CSPC PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-20
- EPS/Forecast: 0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSPC PHARMACEUTICAL News
New
Health Care Roundup: Market Talk
Find insight on Novo Nordisk, CSPC Pharmaceutical Group and more in the latest Market Talks covering Health Care. Continue Reading View Comments
How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story
The Board of Directors of CSPC Pharmaceutical Group announced it has received approval from China's National Medical Products Administration to begin clinical trials for SYH2061 Injection, an ultra-lo...
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals, Inc. Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agre...
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
